Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2003
10/02/2003US20030187022 Pain management; analgesics
10/02/2003US20030187020 Chemical compounds
10/02/2003US20030187013 Central nervous system disorders
10/02/2003US20030187012 Reduction physical cigarette smoking
10/02/2003US20030187009 Analgesics, diarrhea, anticonvulsants, antitussive agents or drug abuse therapy
10/02/2003US20030187007 Inhibitors of protein kinase for the treatment of disease
10/02/2003US20030187006 Method for enhancing cognitive function
10/02/2003US20030187004 Central nervous system disorders; Alzheimer's disease
10/02/2003US20030186999 Purine derivatives having, in particular, antiproliferative properties, and their biological uses
10/02/2003US20030186997 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same
10/02/2003US20030186994 Anticholesterol agents; cardiovascular disorders
10/02/2003US20030186992 Remedial agent for anxiety neurosis or depression and piperazine derivative
10/02/2003US20030186989 Antihistamines; respiratory system disorders
10/02/2003US20030186988 Lymphocyte disease; autoimmune disease
10/02/2003US20030186986 Agent for improving learning or memory
10/02/2003US20030186981 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases
10/02/2003US20030186975 Coumarin derivatives with comt inhibiting activity
10/02/2003US20030186974 Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
10/02/2003US20030186968 Psychological disorders; central nervous system disorders
10/02/2003US20030186966 Antiinflammatory agents; autoimmune disease; antiallergens
10/02/2003US20030186964 Piperdines for use as orexin receptor antagonists
10/02/2003US20030186960 Nervous system regeneration
10/02/2003US20030186959 Central nervous system disorders
10/02/2003US20030186953 Alzheimer's, Parkinson's disease, brain disorders
10/02/2003US20030186946 Suppression of cytotoxic protein conformers
10/02/2003US20030186945 Method of preparing and use of prodrugs of betulinic acid derivatives
10/02/2003US20030186941 Cyclopenteneone derivatives
10/02/2003US20030186901 Method of inhibiting neurotrophin-receptor binding
10/02/2003US20030186897 Derivatives of branched-chain lipophilic molecules and uses thereof
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186891 Polypeptide comprising fragments of matrix extracellular phosphoglycoproteins used to control calcitriol concentrations in cells, for prophylaxis of bone disorders
10/02/2003US20030186889 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/02/2003US20030186880 Combination therapy using trefoil peptides
10/02/2003US20030186877 Helical peptidomimetics
10/02/2003US20030186870 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
10/02/2003US20030186842 Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family
10/02/2003US20030186838 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
10/02/2003US20030186424 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
10/02/2003US20030186391 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purpose
10/02/2003US20030186337 Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
10/02/2003US20030186333 Comprises nervous system polypeptide for diagnosis, prognosis, treatment and evaluation of neurodegenerative disorders
10/02/2003US20030186325 Method of screening for inhibitors of osteopontin
10/02/2003US20030186321 Comprises polypeptide having antitumor, immunomodulatory and viricidal activity for treating leukemia, hepatitis and autoimmune diseases
10/02/2003US20030186305 Novel proteins
10/02/2003US20030186290 Gene involved in CADASIL, method of diagnosis and therapeutic application
10/02/2003US20030186284 Method of screening ptp ç activitiy promoter or inhibitor
10/02/2003US20030186264 Comprises enzymatic polypeptide for diagnosis and treatment of genetic disorders; drug screening; immunoassay; high throughput assay
10/02/2003US20030186253 Fibroblast growth factor-13
10/02/2003US20030185908 Monoamine oxidase (MAO) inhibitors and uses thereof
10/02/2003US20030185873 Provides reversible local anesthesia when implanted or injected in a patient, and a non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia
10/02/2003US20030185855 Which has lost its transducing properties as a result of a DNA sequence change in the gene coding for Vmw65 protein; expressable heterologous gene inserted; under the control of the immediate early 1 gene enhancer of cytomegalovirus
10/02/2003US20030185824 Administering an inhibitor of the CD2/LFA-3 interaction, in combination with an auxiliary agent, such as UV-B
10/02/2003US20030185816 Modified immunogenic self-protein and a surfactant capable of acting as a solubiliser, especially modified human TNF alpha and cetylpyridinium chloride
10/02/2003US20030185815 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/02/2003US20030185794 Such as a pleiotrophin or midkine molecule in a pharmaceutically acceptable carrier.
10/02/2003CA2761440A1 Fredericamycin derivatives
10/02/2003CA2756798A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003CA2480385A1 Alkoxypyridine derivatives as nitric oxide synthase inhibitors
10/02/2003CA2480384A1 Phenanthridinones as parp inhibitors
10/02/2003CA2480302A1 Compositions and methods for treating and preventing necrosis
10/02/2003CA2480219A1 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
10/02/2003CA2480100A1 Alertness bar
10/02/2003CA2480039A1 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
10/02/2003CA2480016A1 Histone deacetylase: novel molecular target of neurotoxicity
10/02/2003CA2479908A1 Calcineurin activator
10/02/2003CA2479881A1 Hif hydroxylase inhibitors
10/02/2003CA2479722A1 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003CA2479718A1 Analgesics for nasal administration
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479668A1 Crystalline forms of quetiapine hemifumarate
10/02/2003CA2479555A1 Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients
10/02/2003CA2479372A1 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
10/02/2003CA2479306A1 Egfr ligands and methods of use
10/02/2003CA2479279A1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
10/02/2003CA2479277A1 Fused bicyclic pyrimidine derivatives
10/02/2003CA2479259A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003CA2479256A1 Phosphate prodrugs of fluorooxindoles
10/02/2003CA2479252A1 Sustained release formulation of tramadol
10/02/2003CA2479214A1 A substance with sedative effect
10/02/2003CA2479150A1 Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
10/02/2003CA2478913A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
10/02/2003CA2477812A1 A non-selective cation channel in neural cells and methods for treating brain swelling
10/02/2003CA2477771A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
10/02/2003CA2474637A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
10/01/2003EP1348708A1 Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
10/01/2003EP1348707A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/01/2003EP1348704A1 Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them
10/01/2003EP1348701A1 (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
10/01/2003EP1348466A2 Method for treating pain with adenosine-tetraphosphates
10/01/2003EP1348433A1 Thiazol-2-yl-imine compounds as PDE-7 inhibitors
10/01/2003EP1348029A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/01/2003EP1347990A2 Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
10/01/2003EP1347982A2 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347979A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
10/01/2003EP1347978A1 Novel substituted imidazotriazinones as pde ii-inhibitors
10/01/2003EP1347976A2 Tricyclic purine compounds and their analogs as inhibiotrs of cytokine signalling
10/01/2003EP1347974A1 Aminotriazolopyridiine derivatives as adenosine receptor ligands
10/01/2003EP1347972A1 Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
10/01/2003EP1347971A1 Thiazolyl inhibitors of tec family tyrosine kinases
1 ... 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 ... 1833